ESR1 and breast cancer: Proliferation assays using human epithelialtriple-negative MDA-MB-231 and ER+ MCF7135 breast cancer cell lines demonstrated increasing antiproliferativeeffects when OT was administered in a dose-dependent manner (1–100nM), consistent with previous data.136